pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,319 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT825Endpoints628BioPharma Dive239onclive165Fierce Biotech91BioSpace90raps32globenewswire health28fda recalls
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • STAT+: Elevance sues government over $115 million tied to Medicare Advantage star ratings
    The health insurer says CMS didn't calculate its star ratings appropriately.
    STAT · 28d ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.
    STAT · 28d ago↗ source
  • STAT+: What does DeGette’s loss mean for pharma?
    Colorado Democratic Rep. Diana DeGette, who lost her primary, was knowledgeable about biopharma, if not always a friend to the industry.
    STAT · 28d ago↗ source
← prev
page 18 of 53
next →
22
fda press21
fda medwatch17
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • A PureTech startup banks $180M for a new IPF drug
    Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
    BioPharma Dive · 28d ago↗ source
  • Roche KRAS drug succeeds in head-to-head lung cancer study
    The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
    BioPharma Dive · 28d ago↗ source
  • STAT+: Roche drug sets new standard for KRAS-driven lung cancer
    Biotech's bull market, Vertex's gene therapy expansion, and more news from The Readout
    STAT · 28d ago↗ source
  • STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more
    U.S. judge blocked a Colorado state panel from placing a cap on the price of Amgen's blockbuster drug Enbrel
    STAT · 28d ago↗ source
  • STAT+: U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug
    A federal judge blocked a Colorado state panel from placing a cap on the price of Enbrel, a blockbuster drug sold by Amgen
    STAT · 28d ago↗ source
  • STAT+: More frequent, more intense, and longer heat waves pose health risks for Americans
    The presidential fitness test is back, surprising new data on the health risks of obesity, and more Morning Rounds news
    STAT · 28d ago↗ source
  • STAT+: Halfway into the year, biotech is booming
    The biotech stock rally that began in April 2025 has not stopped, and if anything, has accelerated.
    STAT · 28d ago↗ source
  • Opinion: Teens are turning to chatbots for mental health help. We need rules to keep them safe
    The share of young people using AI chatbots for mental health advice rose more than 40% in a single year, researcher writes.
    STAT · 28d ago↗ source
  • Opinion: CDC leadership continues to try to manufacture a scientific debate on vaccines where none exists
    CDC leadership continues to try manufacture a scientific debate on vaccines where none exists, writes Ben Lopman.
    STAT · 28d ago↗ source
  • STAT+: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong
    Companies are being too conservative in how they interpret FDA's AI guidance, but the agency can do more to help, too, Tala Fakhouri says.
    STAT · 28d ago↗ source
  • STAT+: A year after distressed buyout, what’s become of Bluebird Bio?
    Bluebird Bio was a dark biotech morality tale when David Meek bought it. He says the new company, Genetix, is already making money.
    STAT · 28d ago↗ source
  • The new presidential fitness test is a positive step, not the solution, experts say
    Physical activity needs to be fun to keep kids engaged. And the test risks embarrassing them, instead.
    STAT · 28d ago↗ source
  • STAT+: A ‘historic’ FDA clearance raises the question: Is the LLM an interface or the decision-maker?
    The newly cleared device is based around an app that helps a patient manage their diabetes using a treatment plan defined by their doctor.
    STAT · 28d ago↗ source
  • Statins and blood pressure drugs changing health risks of obesity, study suggests
    New research shows obesity patients over 40 are managing blood pressure and cholesterol as well as healthy-weight peers, but younger adults remain at risk.
    STAT · 28d ago↗ source
  • BridgeBio gets funding for drug launch; United buys into cell therapy
    Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.
    BioPharma Dive · 29d ago↗ source
  • STAT+: The moment Anthropic convinced me it’s serious about science
    AI Prognosis: The release of Claude Science suggests big model makers are getting serious about real science, and not just flashy problems.
    STAT · 29d ago↗ source
  • STAT+: Synthetic biology researchers think they’ve made a cell. Is it alive?
    Researchers have created what they say may count as the first synthetic cell, and have started a public benefit corporation to share the technology with other scientists. It’s a piece…
    STAT · 29d ago↗ source
  • Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
    The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.
    BioPharma Dive · 29d ago↗ source
  • STAT+: Pharmalittle: We’re reading about Anthropic drug development goals, Trump drug plan snags, and more
    Anthropic announced the availability of Claude Science, which optimizes its large language model for use in scientific labs and by drugmakers
    STAT · 29d ago↗ source
  • STAT+: More signs that GLP-1s may help with peripheral artery disease
    Anthropic will begin developing drugs, BridgeBio pockets a billion, and more biotech news from The Readout
    STAT · 29d ago↗ source
  • 5 FDA decisions to watch in the third quarter of 2026
    A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.
    BioPharma Dive · 29d ago↗ source
  • Abivax shares surge as worries subside over immune drug’s cancer risk
    According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.
    BioPharma Dive · 29d ago↗ source